{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:16:32Z","timestamp":1784546192137,"version":"3.55.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD21\/0002\/0041"],"award-info":[{"award-number":["RD21\/0002\/0041"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40123-025-01211-1","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T16:20:39Z","timestamp":1753460439000},"page":"2253-2281","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-World Outcomes of Allogeneic Immunosafe Plasma Rich in Growth Factors Eye Drops for Refractory Ocular Surface Diseases: A Prospective Observational Study"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1885-2335","authenticated-orcid":false,"given":"Rosa","family":"Alvarado-Villacorta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3740-3754","authenticated-orcid":false,"given":"Jes\u00fas","family":"Merayo-Lloves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5884-6741","authenticated-orcid":false,"given":"Ronald M.","family":"S\u00e1nchez-\u00c1vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3151-0201","authenticated-orcid":false,"given":"Bel\u00e9n","family":"Alfonso-Bartolozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4600-427X","authenticated-orcid":false,"given":"Carlos","family":"Lisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9197-5847","authenticated-orcid":false,"given":"Luis","family":"Fern\u00e1ndez-Vega-Cueto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0373-8209","authenticated-orcid":false,"given":"Jos\u00e9 F.","family":"Alfonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8386-5303","authenticated-orcid":false,"given":"Eduardo","family":"Anitua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"issue":"25","key":"1211_CR1","first-page":"00276","volume":"S0002\u20139394","author":"F Stapleton","year":"2025","unstructured":"Stapleton F, Arg\u00fceso P, Asbell P, et\u00a0al. TFOS DEWS III digest report. Am J Ophthalmol. 2025;S0002\u20139394(25):00276\u201384.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"1211_CR2","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","volume":"15","author":"AJ Bron","year":"2017","unstructured":"Bron AJ, de Paiva CS, Chauhan SK, et\u00a0al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15(3):438\u2013510. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.011.","journal-title":"Ocul Surf"},{"issue":"9","key":"1211_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.949202","volume":"6","author":"M Soifer","year":"2022","unstructured":"Soifer M, Azar NS, Mousa HM, Perez VL. Ocular surface inflammatory disorders (OSID): a collective of systemic etiologies which cause or amplify dry eye syndrome. Front Med (Lausanne). 2022;6(9): 949202.","journal-title":"Front Med (Lausanne)"},{"issue":"25","key":"1211_CR4","first-page":"00274","volume":"S0002\u20139394","author":"L Jones","year":"2025","unstructured":"Jones L, Craig JP, Markoulli M, et\u00a0al. TFOS DEWS III management and therapy report. Am J Ophthalmol. 2025;S0002\u20139394(25):00274.","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"1211_CR5","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.transci.2017.07.023","volume":"56","author":"G Giannaccare","year":"2017","unstructured":"Giannaccare G, Versura P, Buzzi M, Primavera L, Pellegrini M, Campos EC. Blood derived eye drops for the treatment of cornea and ocular surface diseases. Transfus Apher Sci. 2017;56(4):595\u2013604.","journal-title":"Transfus Apher Sci"},{"issue":"11","key":"1211_CR6","doi-asserted-by":"publisher","first-page":"1500160","DOI":"10.3389\/fmed.2024.1500160","volume":"16","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Li N, Ge Z, Li F. Blood component therapy for dry eye disease: a systematic review and network meta-analysis. Front Med (Lausanne). 2024;16(11):1500160.","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"1211_CR7","doi-asserted-by":"publisher","first-page":"6066","DOI":"10.1167\/iovs.11-7302","volume":"52","author":"E Anitua","year":"2011","unstructured":"Anitua E, Sanchez M, Merayo-Lloves J, De la Fuente M, Muruzabal F, Orive G. Plasma rich in growth factors (PRGF-Endoret) stimulates proliferation and migration of primary keratocytes and conjunctival fibroblasts and inhibits and reverts TGF-beta1-Induced myodifferentiation. Invest Ophthalmol Vis Sci. 2011;52(9):6066\u201373.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1211_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.exer.2013.12.005","volume":"119","author":"E Anitua","year":"2014","unstructured":"Anitua E, Muruzabal F, De la Fuente M, Merayo-Lloves J, Orive G. Effects of heat-treatment on plasma rich in growth factors-derived autologous eye drop. Exp Eye Res. 2014;119:27\u201334.","journal-title":"Exp Eye Res"},{"issue":"2","key":"1211_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1159\/000439280","volume":"55","author":"J Merayo-Lloves","year":"2015","unstructured":"Merayo-Lloves J, Sanchez RM, Riestra AC, et\u00a0al. Autologous plasma rich in growth factors eyedrops in refractory cases of ocular surface disorders. Ophthalmic Res. 2015;55(2):53\u201361.","journal-title":"Ophthalmic Res"},{"issue":"7","key":"1211_CR10","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1007\/s10792-021-01788-z","volume":"41","author":"AL Sabater","year":"2021","unstructured":"Sabater AL, Mousa HM, Quinones X, et\u00a0al. Use of autologous plasma rich in growth factors fibrin membrane in the surgical management of ocular surface diseases. Int Ophthalmol. 2021;41(7):2347\u201358.","journal-title":"Int Ophthalmol"},{"issue":"1","key":"1211_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/14712598.2021.1945030","volume":"22","author":"E Anitua","year":"2022","unstructured":"Anitua E, de la Sen-Corcuera B, Orive G, et\u00a0al. Progress in the use of plasma rich in growth factors in ophthalmology: from ocular surface to ocular fundus. Expert Opin Biol Ther. 2022;22(1):31\u201345.","journal-title":"Expert Opin Biol Ther"},{"key":"1211_CR12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jtos.2022.04.007","volume":"25","author":"M Soifer","year":"2022","unstructured":"Soifer M, Tovar A, Wang M, et\u00a0al. A multicenter report of the use of plasma rich in growth factors (PRGF) for the treatment of patients with ocular surface diseases in North America. Ocul Surf. 2022;25:40\u20138.","journal-title":"Ocul Surf"},{"issue":"5","key":"1211_CR13","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1080\/02713683.2023.2173237","volume":"48","author":"E Anitua","year":"2023","unstructured":"Anitua E, de la Fuente M, S\u00e1nchez-\u00c1vila RM, de la Sen-Corcuera B, Merayo-Lloves J, Muruz\u00e1bal F. Beneficial effects of plasma rich in growth factors (PRGF) versus autologous serum and topical insulin in ocular surface cells. Curr Eye Res. 2023;48(5):456\u201364.","journal-title":"Curr Eye Res"},{"issue":"22","key":"1211_CR14","doi-asserted-by":"publisher","first-page":"12176","DOI":"10.3390\/ijms222212176","volume":"22","author":"E Anitua","year":"2021","unstructured":"Anitua E, Muruzabal F, Pino A, Prado R, Azkargorta M, Elortza F, Merayo-Lloves J. Proteomic characterization of plasma rich in growth factors and undiluted autologous serum. Int J Mol Sci. 2021;22(22):12176.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"1211_CR15","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/aos.12386","volume":"92","author":"LH Harritsh\u00f8j","year":"2014","unstructured":"Harritsh\u00f8j LH, Nielsen C, Ullum H, Hansen MB, Julian HO. Ready-made allogeneic ABO-specific serum eye drops: production from regular male blood donors, clinical routine, safety and efficacy. Acta Ophthalmol. 2014;92(8):783\u20136.","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"1211_CR16","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1097\/ICO.0000000000000147","volume":"33","author":"J Hwang","year":"2014","unstructured":"Hwang J, Chung SH, Jeon S, Kwok SK, Park SH, Kim MS. Comparison of clinical efficacies of autologous serum eye drops in patients with primary and secondary Sj\u00f6gren syndrome. Cornea. 2014;33(7):663\u20137.","journal-title":"Cornea"},{"issue":"3","key":"1211_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2024.103912","volume":"63","author":"K Chmielewska","year":"2024","unstructured":"Chmielewska K, Janus J, Miko\u0142owska A, Wrzodak K, St\u0105cel M, Antoniewicz-Papis J. Correlation between serum cytokine levels and the effect of allogeneic serum-based eye drops. Transfus Apher Sci. 2024;63(3): 103912.","journal-title":"Transfus Apher Sci"},{"issue":"2","key":"1211_CR18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1365-2125.1979.tb00923.x","volume":"7","author":"WH Steele","year":"1979","unstructured":"Steele WH, Stuart JF, Whiting B, et\u00a0al. Serum, tear and salivary concentrations of methotrexate in man. Br J Clin Pharmacol. 1979;7(2):207\u201311.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1211_CR19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00417-020-04865-8","volume":"259","author":"V Tahmaz","year":"2021","unstructured":"Tahmaz V, Wiesen MHJ, Gehlsen U, et\u00a0al. Detection of systemic immunosuppressants in autologous serum eye drops (ASED) in patients with severe chronic ocular graft versus host disease. Graefes Arch Clin Exp Ophthalmol. 2021;259(1):121\u20138.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"1211_CR20","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1055\/s-2008-1027199","volume":"225","author":"S Harloff","year":"2008","unstructured":"Harloff S, Hartwig D, Kasper K, Wedel T, M\u00fcller M, Geerling G. Epitheliotrophe Kapazit\u00e4t von Serum-Augentropfen gesunder versus immunsupprimierter Patienten mit rheumatoider Arthritis [Epitheliotrophic capacity of serum eye drops from healthy donors versus serum from immunosuppressed patients with rheumatoid arthritis]. Klin Monbl Augenheilkd. 2008;225(3):200\u20136.","journal-title":"Klin Monbl Augenheilkd"},{"issue":"8","key":"1211_CR21","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/bjophthalmol-2012-301668","volume":"96","author":"KG Badami","year":"2012","unstructured":"Badami KG, McKellar M. Allogeneic serum eye drops: time these became the norm? Br J Ophthalmol. 2012;96(8):1151\u20132.","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"1211_CR22","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/aos.12801","volume":"93","author":"PA Stenwall","year":"2015","unstructured":"Stenwall PA, Bergstr\u00f6m M, Seiron P, Sellberg F, Olsson T, Knutson F, Berglund D. Improving the anti-inflammatory effect of serum eye drops using allogeneic serum permissive for regulatory T cell induction. Acta Ophthalmol. 2015;93(7):654\u20137.","journal-title":"Acta Ophthalmol"},{"issue":"5","key":"1211_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2024.103991","volume":"63","author":"J Janus","year":"2024","unstructured":"Janus J, Chmielewska K, Antoniewicz-Papis J. Allogeneic serum-based eye drops may give better results than autologous drops in Sj\u00f6gren\u2019s syndrome dry eye. Transfus Apher Sci. 2024;63(5): 103991.","journal-title":"Transfus Apher Sci"},{"issue":"4","key":"1211_CR24","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/tme.13068","volume":"34","author":"F Dormann","year":"2024","unstructured":"Dormann F, H\u00e4hnel V, M\u00fcller V, Burkhardt R, Offner R. Allogenic and autologous nondiluted serum eye drops-validation strategy compliant with good manufacturing practice. Transfus Med. 2024;34(4):319\u201325.","journal-title":"Transfus Med"},{"issue":"1","key":"1211_CR25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S1542-0124(12)70004-6","volume":"1","author":"GN Foulks","year":"2003","unstructured":"Foulks GN. Challenges and pitfalls in clinical trials of treatment for dry eye. Ocul Surf. 2003;1(1):20\u201330.","journal-title":"Ocul Surf"},{"issue":"7","key":"1211_CR26","first-page":"3612","volume":"65","author":"R Alvarado","year":"2024","unstructured":"Alvarado R, Alfonso-Sanchez J, Merayo-Lloves J. Comparative efficacy and safety of allogeneic blood-based eye drops for ocular surface diseases: a systematic review of randomized clinical trials. Invest Ophthalmol Vis Sci. 2024;65(7):3612.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"1211_CR27","doi-asserted-by":"publisher","first-page":"e605","DOI":"10.1111\/aos.12710","volume":"93","author":"E Anitua","year":"2015","unstructured":"Anitua E, Muruzabal F, Tayebba A, et\u00a0al. Autologous serum and plasma rich in growth factors in ophthalmology: preclinical and clinical studies. Acta Ophthalmol. 2015;93(8):e605\u201314.","journal-title":"Acta Ophthalmol"},{"issue":"5","key":"1211_CR28","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1089\/jop.2016.0166","volume":"33","author":"RM Sanchez-Avila","year":"2017","unstructured":"Sanchez-Avila RM, Merayo-Lloves J, Riestra AC, et\u00a0al. The effect of immunologically safe plasma rich in growth factor eye drops in patients with Sj\u00f6gren syndrome. J Ocul Pharmacol Ther. 2017;33(5):391\u20139.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"3","key":"1211_CR29","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jtos.2017.05.001","volume":"15","author":"JS Wolffsohn","year":"2017","unstructured":"Wolffsohn JS, Arita R, Chalmers R, et\u00a0al. TFOS DEWS II diagnostic methodology report. Ocul Surf. 2017;15(3):539\u201374.","journal-title":"Ocul Surf"},{"issue":"1","key":"1211_CR30","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1177\/1120672118818943","volume":"30","author":"RM Sanchez-Avila","year":"2020","unstructured":"Sanchez-Avila RM, Merayo-Lloves J, Muruzabal F, Orive G, Anitua E. Plasma rich in growth factors for the treatment of dry eye from patients with graft versus host diseases. Eur J Ophthalmol. 2020;30(1):94\u2013103.","journal-title":"Eur J Ophthalmol"},{"issue":"5","key":"1211_CR31","doi-asserted-by":"publisher","first-page":"928","DOI":"10.3390\/medicina59050928","volume":"59","author":"J Lozano-Sanroma","year":"2023","unstructured":"Lozano-Sanroma J, Barros A, Alcalde I, et\u00a0al. Impact of plasma rich in growth factors (PRGF) eye drops on ocular redness and symptomatology in patients with dry eye disease. Medicina (Kaunas). 2023;59(5):928.","journal-title":"Medicina (Kaunas)"},{"issue":"4","key":"1211_CR32","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1167\/iovs.10-6997f","volume":"52","author":"A Tomlinson","year":"2011","unstructured":"Tomlinson A, Bron AJ, Korb DR, et\u00a0al. The International Workshop on Meibomian Gland Dysfunction: report of the Diagnosis Subcommittee. Invest Ophthalmol Vis Sci. 2011;52(4):2006\u201349.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1211_CR33","unstructured":"WHO model lists of essential medicines 2023. https:\/\/www.who.int\/publications\/i\/item\/WHO-MHP-HPS-EML-2023.02. 2023"},{"issue":"14","key":"1211_CR34","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.2147\/OPTH.S265701","volume":"12","author":"J You","year":"2020","unstructured":"You J, Hodge C, Hoque M, Petsoglou C, Sutton G. Human platelets and derived products in treating ocular surface diseases\u2014A systematic review. Clin Ophthalmol. 2020;12(14):3195\u2013210.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"1211_CR35","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12929-023-00972-w","volume":"30","author":"T Burnouf","year":"2023","unstructured":"Burnouf T, Chou ML, Lundy DJ, Chuang EY, Tseng CL, Goubran H. Expanding applications of allogeneic platelets, platelet lysates, and platelet extracellular vesicles in cell therapy, regenerative medicine, and targeted drug delivery. J Biomed Sci. 2023;30(1):79.","journal-title":"J Biomed Sci"},{"issue":"4","key":"1211_CR36","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3390\/diseases12040076","volume":"12","author":"J Lozano-Sanroma","year":"2024","unstructured":"Lozano-Sanroma J, Barros A, Alcalde I, et\u00a0al. Efficacy and safety of plasma rich in growth factor in patients with congenital aniridia and dry eye disease. Diseases. 2024;12(4):76.","journal-title":"Diseases"},{"key":"1211_CR37","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41433-023-02904-2","volume":"38","author":"S Ghalibafan","year":"2024","unstructured":"Ghalibafan S, Osei KA, Amescua G, Sabater AL. Efficacy of plasma rich in growth factors (PRGF) in stage 1 neurotrophic keratitis. Eye. 2024;38:1390\u20131.","journal-title":"Eye"},{"issue":"5","key":"1211_CR38","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.3390\/jcm12051841","volume":"12","author":"A Barros","year":"2023","unstructured":"Barros A, Lozano-Sanroma J, Queiruga-Pi\u00f1eiro J, et\u00a0al. Recovery of corneal innervation after treatment in dry eye disease: a confocal microscopy study. J Clin Med. 2023;12(5):1841.","journal-title":"J Clin Med"},{"issue":"9","key":"1211_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.946828","volume":"24","author":"M Wang","year":"2022","unstructured":"Wang M, Yennam S, Pflugfelder S. Initial experiences using plasma rich in growth factors to treat keratoneuralgia. Front Med (Lausanne). 2022;24(9): 946828.","journal-title":"Front Med (Lausanne)"},{"key":"1211_CR40","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jtos.2021.09.003","volume":"23","author":"M Wang","year":"2022","unstructured":"Wang M, Yennam S, McMillin J, et\u00a0al. Combined therapy of ocular surface disease with plasma rich in growth factors and scleral contact lenses. Ocul Surf. 2022;23:162\u20138.","journal-title":"Ocul Surf"},{"issue":"9","key":"1211_CR41","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.3390\/jcm10091939","volume":"10","author":"JM S\u00e1nchez-Gonz\u00e1lez","year":"2021","unstructured":"S\u00e1nchez-Gonz\u00e1lez JM, Alonso-Aliste F, Borroni D, et\u00a0al. Plasma rich in growth factors (PRGF) in transepithelial photorefractive keratectomy (TPRK). J Clin Med. 2021;10(9):1939.","journal-title":"J Clin Med"},{"issue":"3","key":"1211_CR42","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024139","volume":"100","author":"RM Sanchez-Avila","year":"2021","unstructured":"Sanchez-Avila RM, Uribe-Badillo EE, Sanz JF, et\u00a0al. Plasma rich in growth factors versus mitomycin C in photorefractive keratectomy. Medicine (Baltimore). 2021;100(3): e24139.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"1211_CR43","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/vision5030034","volume":"5","author":"RM S\u00e1nchez-\u00c1vila","year":"2021","unstructured":"S\u00e1nchez-\u00c1vila RM, Uribe-Badillo E, Fern\u00e1ndez-Vega Gonz\u00e1lez C, et\u00a0al. Use of plasma rich in growth factors and ReGeneraTing agent matrix for the treatment of corneal diseases. Vision (Basel). 2021;5(3):34.","journal-title":"Vision (Basel)"},{"key":"1211_CR44","unstructured":"Gea-Navarrete S, Montero-Hern\u00e1ndez M, Gallego-Lago I, Santiuste Rom\u00e1n A, Montesinos-Orti S, Soler-Company E. Resultados en salud y aspectos f\u00e1rmaco-econ\u00f3micos del tratamiento con PRGF-Endoret en ojo seco. Rev. OFIL.ILAPHAR. 2021; 31 (4): 357\u2013360."},{"issue":"14","key":"1211_CR45","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.2147\/OPTH.S252253","volume":"17","author":"B de la Sen-Corcuera","year":"2020","unstructured":"de la Sen-Corcuera B, Montero-Iruzubieta J, S\u00e1nchez-\u00c1vila RM, et\u00a0al. Plasma rich in growth factors for the treatment of cicatrizing conjunctivitis. Clin Ophthalmol. 2020;17(14):1619\u201327.","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"1211_CR46","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000487951","volume":"60","author":"RM Sanchez-Avila","year":"2018","unstructured":"Sanchez-Avila RM, Merayo-Lloves J, Fernandez ML, et\u00a0al. Plasma rich in growth factors for the treatment of dry eye after LASIK surgery. Ophthalm Res. 2018;60(2):80\u20136.","journal-title":"Ophthalm Res"},{"issue":"11","key":"1211_CR47","first-page":"97","volume":"1","author":"RM S\u00e1nchez-Avila","year":"2018","unstructured":"S\u00e1nchez-Avila RM, Merayo-Lloves J, Fern\u00e1ndez ML, et\u00a0al. Plasma rich in growth factors eye drops to treat secondary ocular surface disorders in patients with glaucoma. Int Med Case Rep J. 2018;1(11):97\u2013103.","journal-title":"Int Med Case Rep J"},{"issue":"3","key":"1211_CR48","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s10792-017-0582-7","volume":"38","author":"RM Sanchez-Avila","year":"2018","unstructured":"Sanchez-Avila RM, Merayo-Lloves J, Riestra AC, et\u00a0al. Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops. Int Ophthalmol. 2018;38(3):1193\u2013204.","journal-title":"Int Ophthalmol"},{"issue":"22","key":"1211_CR49","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007000","volume":"96","author":"A Guarnieri","year":"2017","unstructured":"Guarnieri A, Alfonso-Bartolozzi B, Ciufo G, Moreno-Monta\u00f1\u00e9s J, Gil-Bazo I. Plasma rich in growth factors for the treatment of rapidly progressing refractory corneal melting due to erlotinib in nonsmall cell lung cancer. Medicine (Baltimore). 2017;96(22): e7000.","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"1211_CR50","first-page":"359","volume":"3","author":"RM S\u00e1nchez-\u00c1vila","year":"2016","unstructured":"S\u00e1nchez-\u00c1vila RM, Merayo-Lloves JM. Neurotrophic ulcer after cataract surgery: new treatment. EC Opthalmology. 2016;3(5):359\u201365.","journal-title":"EC Opthalmology"},{"issue":"2","key":"1211_CR51","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1159\/000444496","volume":"56","author":"J Merayo-Lloves","year":"2016","unstructured":"Merayo-Lloves J, Sanchez-Avila RM, Riestra AC, et\u00a0al. Safety and efficacy of autologous plasma rich in growth factors eye drops for the treatment of evaporative dry eye. Ophthalmic Res. 2016;56(2):68\u201373.","journal-title":"Ophthalmic Res"},{"key":"1211_CR52","unstructured":"Vendreli C, Piludu S, Mantaras J, et\u00a0al. PRGF-ENDORET en la queratopat\u00eda por s\u00edndrome de ojo seco severo. 46 Congreso de la Sociedad Catalana de Oftalmolog\u00eda. Noviembre 2015. Barcelona. Available from: https:\/\/www.scoft.cat\/oftalmologia2015\/docs\/comunicaciones\/20_comunicados.pdf"},{"issue":"13","key":"1211_CR53","first-page":"3671","volume":"55","author":"EL Valdez Payan","year":"2014","unstructured":"Valdez Payan EL, Fernandez O, Velasco R, et\u00a0al. Plasma rich in growth factors (PRGF) compared with autologous serum for dry eye treatment. Invest Ophthalmol Vis Sci. 2014;55(13):3671.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"1211_CR54","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1097\/ICO.0b013e31820d86d6","volume":"30","author":"S L\u00f3pez-Plandolit","year":"2011","unstructured":"L\u00f3pez-Plandolit S, Morales MC, Freire V, Grau AE, Dur\u00e1n JA. Efficacy of plasma rich in growth factors for the treatment of dry eye. Cornea. 2011;30(12):1312\u20137.","journal-title":"Cornea"},{"issue":"8","key":"1211_CR55","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1097\/ICO.0b013e3181a81820","volume":"29","author":"S L\u00f3pez-Plandolit","year":"2010","unstructured":"L\u00f3pez-Plandolit S, Morales MC, Freire V, Etxebarr\u00eda J, Dur\u00e1n JA. Plasma rich in growth factors as a therapeutic agent for persistent corneal epithelial defects. Cornea. 2010;29(8):843\u20138.","journal-title":"Cornea"},{"issue":"10","key":"1211_CR56","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1001\/archopht.125.10.1423","volume":"125","author":"GA Rocha","year":"2007","unstructured":"Rocha GA, Acera A, Dur\u00e1n JA. Laser in situ keratomileusis flap necrosis after trigeminal nerve palsy. Arch Ophthalmol. 2007;125(10):1423\u20135.","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"1211_CR57","doi-asserted-by":"publisher","first-page":"293","DOI":"10.22336\/rjo.2021.60","volume":"65","author":"M Rahhal-Ortu\u00f1o","year":"2021","unstructured":"Rahhal-Ortu\u00f1o M, Fern\u00e1ndez-Santodomingo AS, Mart\u00ednez-Rubio C, Barranco-Gonz\u00e1lez H, Almor-Palacios I, Rodrigo-Hern\u00e1ndez A. Use of plasma rich in growth factors (PRGF-Endoret\u00ae) fibrin membrane to cover corneal dellen. Rom J Ophthalmol. 2021;65(3):293\u20135.","journal-title":"Rom J Ophthalmol."},{"issue":"23","key":"1211_CR58","doi-asserted-by":"publisher","first-page":"5711","DOI":"10.3390\/jcm10235711","volume":"10","author":"M Idoipe","year":"2021","unstructured":"Idoipe M, de la Sen-Corcuera B, S\u00e1nchez-\u00c1vila RM, et\u00a0al. Membrane of plasma rich in growth factors in primary pterygium surgery compared to amniotic membrane transplantation and conjunctival autograft. J Clin Med. 2021;10(23):5711.","journal-title":"J Clin Med"},{"issue":"17","key":"1211_CR59","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010242","volume":"97","author":"RM Sanchez-Avila","year":"2018","unstructured":"Sanchez-Avila RM, Merayo-Lloves J, Riestra AC, et\u00a0al. Plasma rich in growth factors membrane as coadjuvant treatment in the surgery of ocular surface disorders. Medicine (Baltimore). 2018;97(17): e0242.","journal-title":"Medicine (Baltimore)"},{"key":"1211_CR60","doi-asserted-by":"crossref","unstructured":"Gemae MR, Patil NS, Yu CW, Agarwal M, Slomovic AR, Chan CC. Use of plasma rich in growth factors for ocular surface disorders: a systematic review. Cornea. 2024","DOI":"10.1097\/ICO.0000000000003711"},{"issue":"3","key":"1211_CR61","doi-asserted-by":"publisher","first-page":"1215848","DOI":"10.3389\/fopht.2023.1215848","volume":"5","author":"M Mancini","year":"2023","unstructured":"Mancini M, Postorino EI, Gargiulo L, Aragona P. Use of allogeneic platelet-rich plasma for the treatment of autoimmune ocular surface disorders: case series. Front Ophthalmol (Lausanne). 2023;5(3):1215848.","journal-title":"Front Ophthalmol (Lausanne)"},{"issue":"4","key":"1211_CR62","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/ICO.0000000000003204","volume":"42","author":"V Romano","year":"2023","unstructured":"Romano V, Bignotti S, Forbice E, Bianchetti A, Almici C, Semeraro F. Allogeneic solid platelet-rich plasma for persistent epithelial neurotrophic defects: a protocol and pilot study. Cornea. 2023;42(4):498\u2013506.","journal-title":"Cornea"},{"issue":"9","key":"1211_CR63","first-page":"6742","volume":"60","author":"M Passilongo","year":"2019","unstructured":"Passilongo M, Bergamo L, Romanelli F, Lovisi A, Colosio M. Comparison between homologous serum eye drops and platelet-rich plasma eye drops as treatment for dry eye disease. Invest Ophthalmol Vis Sci. 2019;60(9):6742.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"1211_CR64","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.3390\/medicina60111764","volume":"60","author":"R Foti","year":"2024","unstructured":"Foti R, Zeppieri M, Foti R, et\u00a0al. Umbilical cord blood-derived products in autoimmune systemic syndromes with severe dryness: a pilot study. Medicina (Kaunas). 2024;60(11):1764.","journal-title":"Medicina (Kaunas)"},{"issue":"10","key":"1211_CR65","first-page":"1268","volume":"14","author":"C Gagliano","year":"2024","unstructured":"Gagliano C, Foti R, Zeppieri M, et\u00a0al. Umbilical cord blood platelet lysate eyedrops for the treatment of severe ocular surface disorders in graft vs host disease patients: clinical study. Life (Basel). 2024;14(10):1268.","journal-title":"Life (Basel)"},{"issue":"4","key":"1211_CR66","doi-asserted-by":"publisher","first-page":"189","DOI":"10.51329\/mehdiophthal1463","volume":"11","author":"R Kamel Farag","year":"2023","unstructured":"Kamel Farag R, Dawood M, Elesawi M. Safety and efficacy of eye drops from umbilical cord blood platelet lysate to treat resistant corneal ulcer. Med Hypothesis Discov Innov Ophthalmol. 2023;11(4):189\u2013202.","journal-title":"Med Hypothesis Discov Innov Ophthalmol"},{"issue":"21","key":"1211_CR67","doi-asserted-by":"publisher","first-page":"6750","DOI":"10.3390\/jcm12216750","volume":"12","author":"J Wong","year":"2023","unstructured":"Wong J, Govindasamy G, Prasath A, et\u00a0al. Allogeneic umbilical cord plasma eyedrops for the treatment of recalcitrant dry eye disease patients. J Clin Med. 2023;12(21):6750.","journal-title":"J Clin Med"},{"issue":"4","key":"1211_CR68","first-page":"347","volume":"19","author":"D Samarkanova","year":"2021","unstructured":"Samarkanova D, Martin S, Bisbe L, et\u00a0al. Barcelona CBED Study Group (Appendix I) Clinical evaluation of allogeneic eye drops from cord blood platelet lysate. Blood Transfus. 2021;19(4):347\u201356.","journal-title":"Blood Transfus"},{"key":"1211_CR69","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/j.1755-3768.2009.01596.x","volume":"87","author":"U Pleyer","year":"2009","unstructured":"Pleyer U, Schlickeiser S. The taming of the shrew? The immunology of corneal transplantation. Acta Ophthalmol. 2009;87:488\u201397.","journal-title":"Acta Ophthalmol"},{"issue":"5","key":"1211_CR70","first-page":"440","volume":"22","author":"R Cantisani","year":"2024","unstructured":"Cantisani R, Del Re V, Toraldo F, et\u00a0al. HLA class I expression on human platelets is highly variable and correlates with distinct allele group frequencies. Blood Transfus. 2024;22(5):440\u20139.","journal-title":"Blood Transfus"},{"issue":"7","key":"1211_CR71","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1097\/ICO.0b013e3180645cd7","volume":"26","author":"CC Chiang","year":"2007","unstructured":"Chiang CC, Lin JM, Chen WL, Tsai YY. Allogeneic serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Cornea. 2007;26(7):861\u20133.","journal-title":"Cornea"},{"issue":"2","key":"1211_CR72","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/sj.eye.6703079","volume":"23","author":"CC Chiang","year":"2009","unstructured":"Chiang CC, Chen WL, Lin JM, Tsai YY. Allogeneic serum eye drops for the treatment of persistent corneal epithelial defect. Eye (Lond). 2009;23(2):290\u20133.","journal-title":"Eye (Lond)"},{"issue":"5","key":"1211_CR73","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1089\/jop.2012.0002","volume":"28","author":"KS Na","year":"2012","unstructured":"Na KS, Kim MS. Allogeneic serum eye drops for the treatment of dry eye patients with chronic graft-versus-host disease. J Ocul Pharmacol Ther. 2012;28(5):479\u201383.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"2","key":"1211_CR74","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40123-020-00239-9","volume":"9","author":"G Giannaccare","year":"2020","unstructured":"Giannaccare G, Carnevali A, Senni C, Logozzo L, Scorcia V. Umbilical cord blood and serum for the treatment of ocular diseases: a comprehensive review. Ophthalmol Ther. 2020;9(2):235\u201348.","journal-title":"Ophthalmol Ther"},{"issue":"4","key":"1211_CR75","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-241138","volume":"14","author":"R Pujari","year":"2021","unstructured":"Pujari R, Deshmukh R, Sheth C, Rajan MS. Maternal finger-prick allogenic blood for persistent corneal epithelial defects. BMJ Case Rep. 2021;14(4): e241138.","journal-title":"BMJ Case Rep"},{"key":"1211_CR76","doi-asserted-by":"crossref","unstructured":"Dunn SP, Stark WJ, Stulting RD, et\u00a0al.; Cornea Donor Study Investigator Group. The effect of ABO blood incompatibility on corneal transplant failure in conditions with low-risk of graft rejection. Am J Ophthalmol. 2009;147(3):432\u2013438","DOI":"10.1016\/j.ajo.2008.09.021"},{"issue":"3","key":"1211_CR77","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/bmt.2016.264","volume":"52","author":"P Solves","year":"2017","unstructured":"Solves P, Carpio N, Carretero C, et\u00a0al. ABO incompatibility does not influence transfusion requirements in patients undergoing single-unit umbilical cord blood transplantation. Bone Marrow Transplant. 2017;52(3):394\u20139.","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"1211_CR78","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/vox.13413","volume":"118","author":"C Gabriel","year":"2023","unstructured":"Gabriel C, Marks DC, Henschler R, Schallmoser K, Burnouf T, Koh MBC. Eye drops of human origin\u2013Current status and future needs: report on the workshop organized by the ISBT Working Party for Cellular Therapies. Vox Sang. 2023;118(4):301\u20139.","journal-title":"Vox Sang"},{"issue":"4","key":"1211_CR79","doi-asserted-by":"publisher","first-page":"e489","DOI":"10.1016\/S2214-109X(20)30488-5","volume":"9","author":"MJ Burton","year":"2021","unstructured":"Burton MJ, Ramke J, Marques AP, et al. The Lancet Global Health Commission on Global Eye Health: vision beyond 2020. Lancet Glob Health. 2021;9(4):e489\u2013e551.","journal-title":"Lancet Glob Health."}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01211-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01211-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01211-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T23:41:02Z","timestamp":1757288462000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-025-01211-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":79,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1211"],"URL":"https:\/\/doi.org\/10.1007\/s40123-025-01211-1","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"assertion":[{"value":"10 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that Eduardo Anitua is the Scientific Director, and Ronald M. S\u00e1nchez-\u00c1vila is a scientist at BTI Biotechnology Institute, a biomedical company that investigates the fields of regenerative medicine and PRGF-Endoret Technology. The other authors declare no conflicts of interest in developing this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The protocol was approved by the Ethics Committees for Investigation with Medicinal Products of the Principality of Asturias (CEImPA 2023.281), and the procedures were conducted in adherence with the tenets of the Declaration of Helsinki. Written informed consents were obtained from every patient and donor before the procedure as routine clinical practice, including permission to use their medical records for scientific purposes. Authorization was granted by the Spanish Agency for Medicines and Health Products (AEMPS) to initiate allogeneic is-ePRGF as compassionate treatment for every enrolled patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}